1. Home
  2. TECX vs RXST Comparison

TECX vs RXST Comparison

Compare TECX & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • RXST
  • Stock Information
  • Founded
  • TECX 2019
  • RXST 1997
  • Country
  • TECX United States
  • RXST United States
  • Employees
  • TECX N/A
  • RXST N/A
  • Industry
  • TECX
  • RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • TECX
  • RXST Health Care
  • Exchange
  • TECX Nasdaq
  • RXST Nasdaq
  • Market Cap
  • TECX 387.1M
  • RXST 385.0M
  • IPO Year
  • TECX 2018
  • RXST 2021
  • Fundamental
  • Price
  • TECX $15.34
  • RXST $8.21
  • Analyst Decision
  • TECX Buy
  • RXST Hold
  • Analyst Count
  • TECX 6
  • RXST 11
  • Target Price
  • TECX $79.17
  • RXST $11.80
  • AVG Volume (30 Days)
  • TECX 480.8K
  • RXST 750.7K
  • Earning Date
  • TECX 11-06-2025
  • RXST 11-06-2025
  • Dividend Yield
  • TECX N/A
  • RXST N/A
  • EPS Growth
  • TECX N/A
  • RXST N/A
  • EPS
  • TECX N/A
  • RXST N/A
  • Revenue
  • TECX N/A
  • RXST $147,059,000.00
  • Revenue This Year
  • TECX N/A
  • RXST N/A
  • Revenue Next Year
  • TECX N/A
  • RXST $6.71
  • P/E Ratio
  • TECX N/A
  • RXST N/A
  • Revenue Growth
  • TECX N/A
  • RXST 27.68
  • 52 Week Low
  • TECX $13.70
  • RXST $6.32
  • 52 Week High
  • TECX $61.07
  • RXST $55.57
  • Technical
  • Relative Strength Index (RSI)
  • TECX 36.96
  • RXST 40.55
  • Support Level
  • TECX $14.62
  • RXST $8.26
  • Resistance Level
  • TECX $15.47
  • RXST $9.38
  • Average True Range (ATR)
  • TECX 0.91
  • RXST 0.42
  • MACD
  • TECX 0.20
  • RXST -0.12
  • Stochastic Oscillator
  • TECX 23.04
  • RXST 4.86

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Share on Social Networks: